about
The clinical application of linagliptin in AsiansSafety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitusPromising therapies for treatment of nonalcoholic steatohepatitis.The potential role of incretin therapy in the hospital setting.Identification and treatment of metabolic complications in pediatric obesity.Incretin effect of Urena lobata leaves extract on structure and function of rats islet β-cells.Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatideNovel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets.Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairmentAlogliptin: a new addition to the class of DPP-4 inhibitors.Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapiesEnhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.The role of incretins in glucose homeostasis and diabetes treatment.A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor.Diabetes and Ramadan: an update on use of glycemic therapies during fastingEffects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study.Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.Incretin therapy--present and future.Extending the reach of Exendin-4: new pathways in the control of body weight and glucose homeostasis.A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancerComparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor AgonistsDiabetes mellitus: new challenges and innovative therapies.Oral Delivery of Pentameric Glucagon-Like Peptide-1 by Recombinant Lactobacillus in Diabetic Rats.Glucose-Dependent Insulinotropic Peptide Level Is Associated with the Development of Type 2 Diabetes Mellitus.Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPEREffects of metformin and sitagliptin on glycolipid metabolism in type 2 diabetic rats on different dietsPPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and OpportunitiesEffect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose.Bariatric surgery: risks and rewards.Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue.Treating type 2 diabetes: incretin mimetics and enhancers.Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.Incretin agents in type 2 diabetes.Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides.A review of gliptins in 2011.Cardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus.Incretin hormones and beta-cell mass expansion: what we know and what is missing?Measuring the nausea-to-emesis continuum in non-human animals: refocusing on gastrointestinal vagal signalingImplications of incretin-based therapies on cardiovascular disease.
P2860
Q26781942-609532AE-D857-4B5D-A35E-BFCC0E1905CFQ27027877-429E3303-FDBB-4DC2-AB6B-BA0746C44E50Q30248578-ABC80D2D-D3A7-4AC3-AD7E-B9D6CECAB2FAQ33792390-3EEB5244-61A4-44F7-953B-EFD4C1F7FFBDQ33893011-BB636B0C-4F8D-4FA3-B904-B8BB0C6D089CQ33896508-0EFC1F9B-DA06-42CD-92EF-56E90214656BQ34133324-B9836AAD-9943-4581-BC5A-4EE375C6D6D3Q34355248-178C2F41-979B-46C9-94FB-8E265162FF6EQ34407868-3F8084B0-818E-4418-8A36-CFC391C68DF3Q34620671-D8C47B18-52AF-4E4D-B36B-47477D8072F2Q34627077-97C4A2C0-FF31-49B3-A850-0E74F3EB8255Q34770205-D35FE64A-0908-46CB-896C-4F32AE19A608Q34901533-4B55810D-4886-4709-97DC-702FAE826FFBQ35138670-503CE2D2-B6FB-4B6E-802D-AC40E8A1DFD1Q35165826-078F1072-93A8-4C87-BE58-EB31A70FDA19Q35192176-B59A402F-74F6-4FC0-827C-E2AEB5E7D212Q35601526-78C6B2F6-3BAA-4CF1-B696-78779C989E8AQ35760283-182C97D6-E8C2-4776-A499-08C7D4B1C403Q35920772-9D0E96D9-FDD7-4398-B4F5-F913CBD7FC47Q36011482-5D6A6BB7-AB48-4E7F-87B6-B7539FC96350Q36073461-43A59821-B996-49A9-A1E1-9D462051EC54Q36117595-552C1871-5A34-4257-9A84-8B91A9DF145EQ36127715-5F9E76E9-E51A-4757-A34C-9ADDF9B2788BQ36717000-E8E7075B-6D36-4661-ADA1-231A22EE2DCBQ36800401-9EBF0755-2950-427E-B250-498B912BA028Q36845293-053D9ED1-2C3F-4A53-8AAE-D2A81739D603Q36959065-AB031DD1-44C5-41DF-81D7-8D34C8E2999AQ37064893-0B71589A-AE11-422B-943B-A3A23C1CD83AQ37223610-3AA9A790-F485-4B95-84BF-5D1CAE38AA71Q37311431-7AD8E42D-FDBD-4D10-8A2E-0529EBDFD372Q37579230-C25F07E8-06D7-4FCF-AFC8-E63AB7E56252Q37609829-7B3ED298-F16A-4879-A5AD-457B833F48B4Q37653125-05273B2C-8655-4327-B8A8-CCD1BD3CACB0Q37772709-2649DF72-3599-4419-B7A1-23AB3B68A54AQ37851584-AF12E472-643F-439F-8073-63CCEA40D0A1Q37965612-8C444969-23D4-4322-ACB8-CE5E12B6A7B2Q38068353-194D01C6-45DE-4461-A358-64AED330B5FEQ38108631-557B616E-3771-4F1F-B600-2AF2C530F280Q38215005-4FFB4C84-F7C5-4654-9B04-08C9E1D81624Q38264374-0B42436D-A5FF-41E0-8DB9-07B398BB2A81
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Incretin-based therapies in type 2 diabetes mellitus.
@en
type
label
Incretin-based therapies in type 2 diabetes mellitus.
@en
prefLabel
Incretin-based therapies in type 2 diabetes mellitus.
@en
P2860
P356
P1476
Incretin-based therapies in type 2 diabetes mellitus.
@en
P2093
Chee W Chia
P2860
P304
P356
10.1210/JC.2007-2109
P407
P577
2008-07-15T00:00:00Z